JP2015506704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506704A5 JP2015506704A5 JP2014555799A JP2014555799A JP2015506704A5 JP 2015506704 A5 JP2015506704 A5 JP 2015506704A5 JP 2014555799 A JP2014555799 A JP 2014555799A JP 2014555799 A JP2014555799 A JP 2014555799A JP 2015506704 A5 JP2015506704 A5 JP 2015506704A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant adenovirus
- nucleic acid
- adenovirus
- heterologous nucleic
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594005P | 2012-02-02 | 2012-02-02 | |
| US61/594,005 | 2012-02-02 | ||
| PCT/US2013/024506 WO2013116778A2 (en) | 2012-02-02 | 2013-02-01 | Immunogenic adenovirus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076878A Division JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506704A JP2015506704A (ja) | 2015-03-05 |
| JP2015506704A5 true JP2015506704A5 (https=) | 2016-03-17 |
| JP6325459B2 JP6325459B2 (ja) | 2018-05-16 |
Family
ID=47714593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555799A Active JP6325459B2 (ja) | 2012-02-02 | 2013-02-01 | 腫瘍関連異種抗原を発現するアデノウイルス |
| JP2018076878A Withdrawn JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076878A Withdrawn JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11155599B2 (https=) |
| EP (1) | EP2809788B1 (https=) |
| JP (2) | JP6325459B2 (https=) |
| KR (1) | KR102100092B1 (https=) |
| CN (2) | CN104271748B9 (https=) |
| AU (1) | AU2013214776B2 (https=) |
| BR (1) | BR112014019049A2 (https=) |
| CA (1) | CA2863523A1 (https=) |
| DK (1) | DK2809788T3 (https=) |
| ES (1) | ES2759785T3 (https=) |
| NZ (1) | NZ628213A (https=) |
| SG (3) | SG10201913795TA (https=) |
| WO (1) | WO2013116778A2 (https=) |
| ZA (1) | ZA201405755B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| WO2013112942A1 (en) | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| CN106029889A (zh) * | 2013-11-22 | 2016-10-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| CN104328140B (zh) * | 2014-10-08 | 2018-06-05 | 兰州大学 | 一种高嗜性膀胱癌靶向性肿瘤杀伤腺病毒 |
| AU2016205208A1 (en) | 2015-01-09 | 2017-07-06 | Etubics Corporation | Methods and compositions for ebola virus vaccination |
| CN107406857B (zh) | 2015-01-09 | 2021-06-29 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
| CN104762269A (zh) * | 2015-03-18 | 2015-07-08 | 红土生物技术有限公司 | 一种增强肿瘤抗原免疫原性的新策略及其在肺癌免疫治疗中的应用 |
| US11149087B2 (en) * | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| ES2987442T3 (es) * | 2015-05-04 | 2024-11-14 | Theriva Biologics S L | Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer |
| CN105087647B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 一种携带Survivin抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN105087648B (zh) * | 2015-06-17 | 2018-05-25 | 深圳益世康宁生物科技有限公司 | 携带mage-a3抗原基因的重组腺相关病毒载体及构建方法与应用 |
| WO2017112797A1 (en) | 2015-12-22 | 2017-06-29 | Thomas Jefferson University | Intra-lesional cmv-based cancer vaccines |
| FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| CN105779480B (zh) * | 2016-03-24 | 2020-03-20 | 成都康景生物科技有限公司 | 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用 |
| JP7466271B2 (ja) * | 2016-03-31 | 2024-04-12 | ザ ヨーロピアン モレキュラー バイオロジー ラボラトリー | アデノウイルスコートタンパク質由来送達賦形剤 |
| CN109789177A (zh) | 2016-05-27 | 2019-05-21 | 德那翠丝有限公司 | 腺病毒和免疫调节剂组合治疗 |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| KR20190098215A (ko) | 2016-12-21 | 2019-08-21 | 멤젠 엘엘씨 | 무장된 복제-가능 종양 분해 아데노바이러스 |
| CA3052090A1 (en) * | 2017-01-30 | 2018-08-02 | Epicentrx, Inc. | Multiple transgene recombinant adenovirus |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| SG11202004680UA (en) | 2017-11-22 | 2020-06-29 | Mesoblast Int Sarl | Cellular compositions and methods of treatment i |
| GB201804468D0 (en) | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| WO2019237371A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 定点插入 ct1.1 基因的 cho 细胞株的构建方法及其用途 |
| CN109081873B (zh) * | 2018-08-10 | 2022-04-22 | 固安鼎泰海规生物科技有限公司 | 一种抗肿瘤重组nmm融合抗原质粒dna疫苗 |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| CN110684800B (zh) * | 2018-11-02 | 2020-11-03 | 深圳益世康宁生物科技有限公司 | 一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020259189A1 (zh) * | 2019-06-27 | 2020-12-30 | 北京太东生物科技有限公司 | Sox11作为精神分裂症诊断标记物的应用 |
| AU2020325825B2 (en) | 2019-08-05 | 2026-02-05 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| US20240293487A1 (en) * | 2020-03-25 | 2024-09-05 | Jin-Woo Choi | Immunoevasive anti-tumor adenovirus |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN111850041A (zh) * | 2020-07-30 | 2020-10-30 | 药鼎(北京)国际细胞医学技术有限公司 | 一种治疗肝癌的含il12双顺反子的病毒构建体及其用途和构建方法 |
| CA3188492A1 (en) | 2020-08-10 | 2022-02-17 | Silviu Itescu | Cellular compositions and methods of treatment |
| EP4602078A2 (en) | 2022-10-11 | 2025-08-20 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| ES2258265T3 (es) | 1994-11-28 | 2006-08-16 | Cell Genesys Inc. | Vectores de replicacion con especificidad tisular. |
| AU5551996A (en) | 1995-04-17 | 1996-11-07 | Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
| US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| WO1998039467A2 (en) | 1997-03-03 | 1998-09-11 | Calydon, Inc. | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof |
| US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
| JP2002530085A (ja) | 1998-11-18 | 2002-09-17 | カンジ，インコーポレイテッド | 後期導入遺伝子の発現を有するウイルスベクター |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| ATE540686T1 (de) | 1999-05-12 | 2012-01-15 | Uab Research Foundation | Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| AU1190901A (en) | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| AU1087701A (en) | 1999-10-15 | 2001-04-30 | Canji, Inc. | Targeted vectors |
| US6756044B1 (en) | 2000-02-09 | 2004-06-29 | Genvec, Inc. | Antigenic complexes and methods |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| US20030211477A1 (en) * | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
| US20060147420A1 (en) * | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| KR20130065723A (ko) * | 2003-06-27 | 2013-06-19 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
| US20070134202A1 (en) | 2003-10-15 | 2007-06-14 | The New Industry Reserch Organization | Cancer gene therapeutic drug |
| WO2009117656A2 (en) * | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| CN101607985B (zh) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体，包含其的组合物，及其用途 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| EP2407177A1 (en) | 2010-07-13 | 2012-01-18 | Institut Gustave Roussy | Adenovirus vaccine vectors |
| EP2383577A1 (en) | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| WO2013112942A1 (en) | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| EP3010519B1 (en) | 2013-06-18 | 2021-04-07 | Dnatrix Inc. | Oncolytic adenovirus for use in a treatment of brain cancer |
-
2013
- 2013-02-01 WO PCT/US2013/024506 patent/WO2013116778A2/en not_active Ceased
- 2013-02-01 JP JP2014555799A patent/JP6325459B2/ja active Active
- 2013-02-01 EP EP13704334.5A patent/EP2809788B1/en active Active
- 2013-02-01 AU AU2013214776A patent/AU2013214776B2/en not_active Ceased
- 2013-02-01 KR KR1020147024570A patent/KR102100092B1/ko not_active Expired - Fee Related
- 2013-02-01 BR BR112014019049A patent/BR112014019049A2/pt not_active Application Discontinuation
- 2013-02-01 CN CN201380017639.4A patent/CN104271748B9/zh not_active Expired - Fee Related
- 2013-02-01 SG SG10201913795TA patent/SG10201913795TA/en unknown
- 2013-02-01 CN CN201910116066.XA patent/CN110042086A/zh active Pending
- 2013-02-01 DK DK13704334T patent/DK2809788T3/da active
- 2013-02-01 SG SG10201606356YA patent/SG10201606356YA/en unknown
- 2013-02-01 SG SG11201404495RA patent/SG11201404495RA/en unknown
- 2013-02-01 ES ES13704334T patent/ES2759785T3/es active Active
- 2013-02-01 US US14/375,842 patent/US11155599B2/en active Active
- 2013-02-01 NZ NZ628213A patent/NZ628213A/en not_active IP Right Cessation
- 2013-02-01 CA CA2863523A patent/CA2863523A1/en not_active Abandoned
-
2014
- 2014-08-05 ZA ZA2014/05755A patent/ZA201405755B/en unknown
-
2018
- 2018-04-12 JP JP2018076878A patent/JP2018138033A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506704A5 (https=) | ||
| JP2018519847A5 (https=) | ||
| ES2759785T3 (es) | Adenovirus que expresan antígenos oncógenos heterólogos | |
| Piper et al. | Glioma stem cells as immunotherapeutic targets: advancements and challenges | |
| Vici et al. | Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies | |
| Anderson et al. | Plasmid DNA and viral vector-based vaccines for the treatment of cancer | |
| Larocca et al. | Viral vector-based therapeutic cancer vaccines | |
| JP7334124B2 (ja) | 個別化ワクチン | |
| JP2016540505A5 (https=) | ||
| Kim et al. | Poxviral vectors for cancer immunotherapy | |
| Biegert et al. | Current development in adenoviral vectors for cancer immunotherapy | |
| Kim et al. | Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures | |
| JP2017501695A5 (https=) | ||
| CN106029889A (zh) | 表达免疫细胞刺激受体激动剂的腺病毒 | |
| Chaurasiya et al. | Viroimmunotherapy for breast cancer: Promises, problems and future directions | |
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| Pol et al. | Oncolytic viruses: a step into cancer immunotherapy | |
| EP4452305A1 (en) | Recombinant mva viruses for intraperitoneal administration for treating cancer | |
| Lundstrom | Alphaviruses in cancer therapy | |
| RU2019125436A (ru) | Новый подход к иммунотерапии, нацеленной на vegfr-2 | |
| JP2020507332A5 (https=) | ||
| White et al. | Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer | |
| Liljenfeldt et al. | A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells | |
| Olsen et al. | Neuro-Oncology Advances | |
| Witt | Cripto-1: potential target for cancer immunotherapy?! |